Shots: Orchard to receive $17.5M up front including $10M in cash & $7.5M as equity investment at a premium to Orchard’s share and is also eligible to receive ~$189.5M as […]readmore
Tags : Commercialize
Shots: MacroGenics receives initial consideration of $55M, including ~$25M up front, $30M as an equity investment in common stock at $31.30/ share & is eligible to receive ~$1.4B as a […]readmore
Shots: iTeos to receive $625M up front & is eligible to receive up to ~$1.45B in milestone upon achievement of certain milestones & royalties on ex-US sales. Both companies will […]readmore
Shots: Verona Pharma to receive $40M including $25M upfront cash and $15M equity interest in Nuance Biotech, and is eligible to receive ~$179M in milestones along with royalties on net […]readmore
Shots: Shoreline to receive $45M up front in cash and is eligible to receive R&D funding, milestones along with royalties, following the achievement of certain milestones The companies will jointly […]readmore
Shots: Kyowa Kirin to receive ~$400M up front and an additional ~$850M as milestones along with royalties on future global sales. Both companies will share global development costs (Ex- Japan […]readmore
Shots: Pharmapark to get exclusive rights to commercialize HD204 and is responsible for local registration, sales, and marketing of the biosimilar in Russia in collaboration with Russian import substitution strategy […]readmore
Shots: Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China SciNeuro to get an […]readmore
Shots: BridgeBio to receive ~$2.45B+ including ~$100M in up front, regulatory and commercial milestones along with royalties on net sales of Infigratinib from Helsinn Group. The agreement is expected to […]readmore
Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales of ADCs Pyxis gets a […]readmore